Anna Katarzyna Furman-Niedziejko

Dr. Anna Katarzyna Furman-Niedziejko

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2026 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
Iwona Gorczyca-GłowackaIwona Gorczyca-Głowacka
Iwona Gorczyca-Głowacka
MTMichał Tarnowski
Michał Tarnowski
AFAnna Katarzyna Furman-Niedziejko
Anna Katarzyna Furman-Niedziejko
AMAgnieszka Major
Agnieszka Major
PLPrzemysław Leszek
Przemysław Leszek
Introduction: not needed Material and methods: not needed Results: not needed Conclusions: not needed

11 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Agata GalasAgata Galas
Agata Galas
RMRobert Morawiec
Robert Morawiec
Agnieszka Kapłon-CieślickaAgnieszka Kapłon-Cieślicka
Agnieszka Kapłon-Cieślicka
KBKATARZYNA BYCZKOWSKA
KATARZYNA BYCZKOWSKA
WFWitold Furmanek
Witold Furmanek
Paweł KrzesińskiPaweł Krzesiński
Paweł Krzesiński
Background/Objectives: Urgent hospitalization due to acutely decompensated heart failure (ADHF) is an unfavorable event in the trajectory of this disease. Patient condition during decompensation frequently limits opportunities to implement and optimize guideline-directed medical therapy (GDMT). To define the tasks of post-hospital care, it is essential to gain knowledge regarding the extent of GDMT implementation on the day of discharge after ADHF episodes. The purpose of this analisis was to evaluate GDMT changes during hospitalization due to ADHF, with a particular emphasis on patients with reduced ejection fraction. Methods: The analysis was conducted in a group of 262 patients hospitalized due to ADHF and with known left ventricular ejection fraction (LVEF). The HEROES study was a prospective, multi-center, observational study. Results: The mean age in the study group (196 men and 66 women) was 67.6 ± 14.6 years, with a mean LVEF of 33.9 ± 14.8%. Six patients died during hospitalization. In the analysis for the whole group (regardless of ejection fraction [EF]), ARNI (angiotensin receptor-neprilysin inhibitor)/ACEI (angiotensin-converting enzyme inhibitor)/ARB (angiotensin receptor blocker) use increased from 63.3% of the subjects at admission to 81.3% at discharge, beta-blocker use increased from 70.6% to 92.6%, MRA (mineralocorticoid receptor antagonist) use increased from 43.1% to 75.8%, and SGLT2i (sodium-glucose co-transporter 2 inhibitor) use increased from 30.1% to 75.0%. ARNI/ACEI/ARB therapy was optimized in 48.4% of the subjects, with optimization rates of 37.9%, 40.2%, and 44.1% for beta-blockers, MRAs, and SGLT2is, respectively. However, only 38 (22.0%) patients reached the level of treatment corresponding to “SGLT2i and ARNI/ACEI/ARB and betablocker and MRA in doses ≥ 50%”. Conclusions: In patients hospitalized due to ADHF in the HEROES study, the use of GDMT at discharge was significantly higher than at admission. In patients with reduced ejection fraction, GDMTs from all drug classes were prescribed to over 80% of patients. However, an insufficient number of patients attained high doses of GDMT, which emphasizes the need for effective dose up-titration in outpatient settings.